Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CSE/MDMA stock hub

CSE/MDMA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CSE/MDMAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

16.3M

Canadian Securities Exchange

Market data

Live price

Current market quote for this ticker.

Current price

CSE/MDMA

In the news

Latest news · CSE/MDMA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 11P50 15.6P75 25.4

Trailing P/En/a

P25 7.4P50 15.6P75 34.3

ROE-62.2

P25 -121.5P50 -40.9P75 0.5

ROIC-34.2

P25 -72.5P50 -16P75 1.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CSE/MDMA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

162

Groups with data

Currency

CAD

Showing 162 of 162 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Canada
Country code	CA
Enterprise value	CAD 15.8M
Exchange	Canadian Securities Exchange
Financial currency	CAD
First seen	2026-05-10
Industry	Biotechnology
Isin	CA71719L1067
Last refreshed	2026-05-10
Market cap	CAD 16.3M
Price	CAD 0.15
Price currency	CAD
Sector	Healthcare
Sic	2836
Symbol	cse/MDMA
Website	https://pharmala.ca

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-10%
EV Earnings	-9.65x
EV/FCF	-17.1x
EV/Sales	17.71x
FCF yield	-5.64%
P/B ratio	7.57x
P/S ratio	18.36x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-161.56%
EBITDA Margin	-159.13%
Gross margin	88.66%
Gross Profit	CAD 788,664
Gross Profit Growth	39.39%
Gross Profit Growth Q	89.62%
Gross Profit Growth3 Y	67.07%
Net Income	CAD -1.6M
Net Income Growth Quarters	2%
Net Income Growth Years	0%
Pretax Margin	-183.55%
Profit Margin	-183.55%
ROA	-25.53
ROCE	-66.65
ROE	-62.2
ROIC	-34.22

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	7.15%
Cagr3y	-21.49%
EPS Growth Quarters	2
EPS Growth Years	0
Revenue Growth	106.79x
Revenue Growth Q	92.63x
Revenue Growth Quarters	3x
Revenue Growth Years	0x
Revenue Growth3 Y	73.14x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	CAD 0.25
Assets	CAD 3.1M
Cash	CAD 577,564
Current Assets	CAD 1.4M
Current Liabilities	CAD 973,421
Equity	CAD 2.2M
Liabilities	CAD 973,421
Long Term Assets	CAD 1.7M
Long Term Liabilities	CAD 0
Net Cash	CAD 577,564
Net Cash By Market Cap	CAD 3.54
Net Cash Growth	-61.75%
Net Debt Equity	CAD -0.27
Tangible Book Value	CAD 414,120
Tangible Book Value Per Share	CAD 0
WACC	8.12

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.42
Inventory Turnover	0.28
Net Working Capital	CAD -165,832
Quick ratio	1.02
Working Capital	CAD 411,732
Working Capital Turnover	CAD 1.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-12.44%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	7.14%
200-day SMA	0.11
3Y total return	-51.61%
50-day SMA	0.12
50-day SMA vs 200-day SMA	50over200
All Time High	0.54
All Time High Change	-72.22%
All Time High Date	2023-05-02
All Time Low	0.02
All Time Low Change	650%
All Time Low Date	2022-05-11
ATR	0.01
Beta	0.7
Beta1y	-0.27
Beta2y	0.64
Ch YTD	36.36
High	0.15
High52	0.2
High52 Date	2026-04-21
High52ch	-23.08%
Low	0.15
Low52	0.09
Low52 Date	2026-04-09
Low52ch	76.47%
Ma50ch	26.16%
Price vs 200-day SMA	32.04%
RSI	57.01
RSI Monthly	52.55
RSI Weekly	65.07
Sharpe ratio	0.52x
Sortino ratio	1.12
Total Return	-12.44%
Tr YTD	36.36
Tr1m	50%
Tr1w	7.14%
Tr3m	50%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	CAD -1.4M
Operating margin	-161.6

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	98,358,384%
Shares Insiders	9.5%
Shares Out	108,887,215
Shares Qo Q	0.81%
Shares Yo Y	12.44%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	CAD -1.5M
Average Volume	405,754.5x
Bv Per Share	0.02
CAPEX	CAD -2,918
Ch1m	50
Ch1w	7.14
Ch1y	7.14
Ch3m	50
Ch3y	-51.61
Ch6m	30.44
Change	3.45%
Change From Open	3.45
Close	0.15
Days Gap	0
Depreciation Amortization	21,559
Dollar Volume	1,192.2
Earnings Date	2026-05-13
EBIT	CAD -1.4M
EBITDA	CAD -1.4M
EPS	CAD -0.02
F Score	2
FCF	CAD -921,290
FCF EV Yield	-5.85x
FCF Per Share	CAD -0.01
Financing CF	-3,048
Fiscal Year End	August
Investing CF	769,261
Is Primary Listing	1
Last Earnings Date	2025-12-19
Last Report Date	2026-02-28
Ma150	0.11
Ma150ch	34.53%
Ma20	0.14
Ma20ch	7.68%
Net CF	-152,159
Next Earnings Date	2026-05-13
Open	0.15
Position In Range	100
Ppne	2,388
Price Date	2026-05-08
Ptbv Ratio	39.44
Relative Volume	0.02x
Revenue	889,568x
SBC By Revenue	66.02x
Share Based Comp	587,294
Tr6m	30.44%
Volume	7,948
Z Score	3.42

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CSE/MDMA pay a dividend?

Capital-return profile for this ticker.

Performance

CSE/MDMA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CSE/MDMA?

Insider, institutional, and short-interest positioning.

Institutional ownership

n/a

Share of float held by funds and institutions

Insider ownership

+9.5%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+12.4%

Negative means the company is buying back shares.

Technical

CSE/MDMA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

57.0

Neutral momentum band

Price vs 200-day MA

+32.0%

50/200-day relationship not available

Beta (5Y)

0.70

Less volatile than the market

Sharpe ratio

0.52

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CSE/MDMA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current cse/MDMA stock rating?

cse/MDMA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full cse/MDMA analysis?

The full report lives at /stocks/cse/MDMA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for cse/MDMA?

The latest report frames cse/MDMA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the cse/MDMA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.